Thursday, April 08, 2021
Shanghai Genechem Co., Ltd. (Genechem), a discovery company dedicated to the discovery of new drug targets and the development of new therapeutic products, today announced the conclusion of a global collaboration with I-Mab, a company global bio-pharmaceutical listed on Nasdaq, to develop and market multiple bispecific antibodies (BsAb) based on the monoclonal antibody developed by Genechem and the antibodies selected by I-MAB.
"This collaboration is the first in a long series that will take advantage of Genechem's Good Research Practices (GRP) and CHAMP antibody discovery platform, its robust bioinformatics database, as well as the expertise in developing synergistic partners, in order to provide globally competitive assets based on innovative targets. We are excited to collaborate with I-Mab, a global leader in oncology and antibody development, to bring more products to meet the unmet clinical needs of patients in China and in the world, ”commented Yueqiong Cao, founder and CEO of Genechem.
